Abstract Number: 861 • 2014 ACR/ARHP Annual Meeting
Ultraviolet B Generates Type 1 Interferon and Induces Autoantibody-Mediated Disease in a Mouse Model of Cutaneous Lupus
Background/Purpose Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions often contain plasmacytoid dendritic cells (pDC). The mechanisms…Abstract Number: 862 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Changes in Subclinical Atherosclerosis As Measured By Carotid Intima Media Thickness (IMT) and Plaque over 5 Years in Women with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Women with SLE have increased rates of subclinical atherosclerosis. We have investigated which risk factors may be related to the increase in subclinical atherosclerosis,…Abstract Number: 860 • 2014 ACR/ARHP Annual Meeting
Inhibition of G Protein βγ Signaling Inhibits Nephritis in Lupus Prone Mice
Background/Purpose G protein-coupled receptors (GPCRs), including chemokine receptors on leukocytes, signal through G protein Gβγ subunits. An important target of Gβγ is phosphoinositide 3 kinase γ…Abstract Number: 879 • 2014 ACR/ARHP Annual Meeting
Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis: Prolonged Remission of Disease Activity in a Long-Term Follow up
Background/Purpose In the recent years, autologous haematopoietic stem cell transplantation (AHSCT) has been shown to represent an effective therapeutic option for patients (pts) suffering from…Abstract Number: 851 • 2014 ACR/ARHP Annual Meeting
A Tailored Approach to Reduce Dose of Anti-TNF Drugs Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Propensity Score-Matched Cohort Study
Background/Purpose: To compare effectiveness, safety and costs of standard versus individually tailored reduced doses of anti-TNF drugs in patients with Ankylosing Spondylitis (AS) after achieving…Abstract Number: 850 • 2014 ACR/ARHP Annual Meeting
Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib
Background/Purpose: Immunopathological studies on synovitis recently identified the mast cell as potential novel therapeutic target in spondyloarthritis (SpA).[1] Mast cells can be targeted by inhibiting…Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…Abstract Number: 848 • 2014 ACR/ARHP Annual Meeting
Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients
Background/Purpose Recent studies have found that a high proportion of female rheumatoid arthritis (RA) patients are chronic carriers of high-risk HPV-strains and that these patients…Abstract Number: 847 • 2014 ACR/ARHP Annual Meeting
Safety of TNF Inhibitor Therapy in Patients Who Have Had a Prior Malignancy
Background/Purpose A few is known about the effects of biologic therapy in patients with a history of a solid cancer. According to the 2012 updated…Abstract Number: 846 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
Background/Purpose: There is a concern that tumor necrosis factor inhibitors (TNFi) may interplay with tumor biology and increase the risk of cancer, in particular cancer…Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting
Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study
Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…Abstract Number: 843 • 2014 ACR/ARHP Annual Meeting
Exercise Is Associated with Protective Cardiovascular Risk Profile Including Increased HDL Particle Number in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased cardiovascular risk. In the general population, exercise improves several cardiovascular risk factors, including HDL cholesterol concentrations. Although…Abstract Number: 842 • 2014 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Background/Purpose: Recently cholesterol treatment guidelines recommend that diabetes (DM) should be considered a CVD risk equivalent to a history of coronary heart disease (CHD). Despite…Abstract Number: 841 • 2014 ACR/ARHP Annual Meeting
Lipid Control and Cardiovascular Risk for Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients
Background/Purpose: Lipid levels are known to be lower in patients with RA compared with the general population; however, differences in cardiovascular (CV) risk associated with…
ACR Meeting Abstracts